Key result
The hs-cTnT, hs-cTnI, and Acc-cTnI assays achieved ≥90% prognostic sensitivity for death and AMI, whereas the Arc-cTnI assay had inferior prognostic sensitivity.
Why the study?
Do different sensitive cardiac troponin assays have comparable prognostic capacity for death and AMI in patients with acute coronary syndrome?
Cohort (n=1,335)
Do different sensitive cardiac troponin assays have comparable prognostic capacity for death and AMI in patients with acute coronary syndrome?
High-sensitivity troponin assays (hs-cTnT, hs-cTnI, Acc-cTnI) demonstrate comparable and superior prognostic sensitivity compared to standard assays for predicting short- and long-term outcomes in acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
May aid troponin-based risk stratification in ACS; leaves open which assay optimizes clinical decisions.
Lindahl et al. (2013) conducted a cohort in Acute coronary syndromes (n=1,335). Sensitive cardiac troponin assays (hs-cTnT, hs-cTnI, Acc-cTnI, Arc-cTnI) was evaluated on Death and acute myocardial infarction at 30 days, and mortality at 1 year. The hs-cTnT, hs-cTnI, and Acc-cTnI assays achieved ≥90% prognostic sensitivity for death and AMI, whereas the Arc-cTnI assay had inferior prognostic sensitivity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: